Compare State Street SPDR S&P Biotech ETF (XBI) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.4, while Direxion Daily FTSE China Bull 3x Shares trades at $28.81. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| XBI | YINN | |
|---|---|---|
Sector | Broad Market / Factor | Leveraged / Inverse |
52-Week High | $164.28 | $56.62 |
52-Week Low | $86.92 | $21.45 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
YINN, a leveraged ETF tracking Chinese stocks, trades at $29.01, down 10.19% amid broad bearish technical signals. Key support lies at $29, with RSI at 24.06 indicating potential oversold conditions. Recent news highlights China's AI investments and export strength, but U.S.-China tech tensions and regulatory scrutiny persist.
The outlook remains clouded by geopolitical risks and leveraged ETF decay, though oversold conditions may offer tactical opportunities. Risks include amplified volatility and policy shifts, requiring cautious positioning given the fund's structure and macro sensitivities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
